Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: CKD


Sodium‐glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease

January 8th 2021

The degree of BP reduction after SGLT2 inhibitor treatment influenced renal composite outcomes in Japanese T2DM patients with CKD, confirming the importance of blood pressure management in T2DM patients with CKD, even when they are under SGLT2 inhibitor treatment (Journal of Diabetes Investigation)

Categories: Nephropathy
Tags: CKD, SGLT2 inhibitors, Type 2 Diabetes

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease:

December 17th 2020

Dapagliflozin reduces the risks of major adverse kidney and cardiovascular events and all-cause mortality in patients with diabetic and non-diabetic chronic kidney disease (The Lancet)

Categories: Medication, News
Tags: CKD, dapagliflozin

Categories: Medication
Tags: CKD, dapagliflozin

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

November 17th 2020

In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events (NEJM)

Categories: Medication, Nephropathy, News
Tags: CKD, sotagliflozin

Categories: Medication, Nephropathy
Tags: CKD, sotagliflozin

Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline

November 16th 2020

The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (Annals of Internal Medicine)

Categories: Nephropathy, News
Tags: CKD

Categories: Nephropathy
Tags: CKD

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

October 26th 2020

In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo (NEJM)

Categories: Nephropathy, News
Tags: CKD, finerenone, Type 2 Diabetes

Categories: Nephropathy
Tags: CKD, finerenone, Type 2 Diabetes

Dapagliflozin in Patients with Chronic Kidney Disease

September 24th 2020

Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo (NEJM)

Categories: Medication, News
Tags: CKD, dapagliflozin

Categories: Medication
Tags: CKD, dapagliflozin

Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease

November 3rd 2019

Our results confirmed that blood pressure management status after treatment with SGLT2 inhibitors influences the extent of change in urinary albumin-creatinine ratio. Stricter blood pressure management is needed to allow the renoprotective effects of sodium-glucose cotransporter 2 inhibitors (Journal of Diabetes Research)

Categories: Hypertension
Tags: CKD, SGLT2 inhibitors

A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease

April 5th 2019

Patients with co-morbid diabetes and kidney disease have education gaps on the management of, and complications of diabetes and kidney disease. Interventions aimed at improving patient education need to be delivered through education resources co-developed by patients and health staff. A targeted education resource in the form of a DVD, addressing these needs, may potentially close these gaps (BMC Nephrology)

Categories: Nephropathy, News
Tags: CKD, co-morbid

Categories: Nephropathy
Tags: CKD, co-morbid

Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

January 23rd 2019

Metformin may be safer for use in CKD than previously considered and may lower the risk of death and cardiovascular events in individuals with stage 3 CKD  (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: CKD, metformin, Type 2 Diabetes

Categories: Medication
Tags: CKD, metformin, Type 2 Diabetes

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease

November 1st 2018

Evidence concerning the efficacy and safety of glucose‐lowering agents for people with diabetes and CKD is limited. SGLT2 inhibitors and GLP‐1 agonists are probably efficacious for lowering glucose levels. Other potential effects of SGLT2 inhibitors include lower BP, lower potassium levels and a reduced risk of heart failure but an increased risk of genital infections. The safety of GLP‐1 agonists is uncertain (Cochrane Library)

Categories: Medication, News
Tags: CKD, GLP1, SGLT2 inhibitors

Categories: Medication
Tags: CKD, GLP1, SGLT2 inhibitors

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

May 17th 2017

All the researches, mentioned in this paper, demonstrating the SGLT2 inhibitors with their novel mechanism and associated benefits on glucose-lowering, renoprotection, body weight, CV safety, etc. have proved to be promising choices either as monotherapy or as combination therapy for patients with DKD (Cardiovascular Diabetology)

Categories: Medication, News
Tags: CKD, SGLT2 inhibitors

Categories: Medication
Tags: CKD, SGLT2 inhibitors

Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease

February 7th 2017

Metformin use in patients with moderate CKD, CHF, or CLD with hepatic impairment is associated with improvements in key clinical outcomes. Our findings support the recent changes in metformin labeling (Annals of Internal Medicine)

Categories: Medication, News
Tags: CHF, CKD, CLD, metformin

Categories: Medication
Tags: CHF, CKD, CLD, metformin

National Chronic Kidney Disease Audit

January 17th 2017

Chronic Kidney Disease (CKD) is a long-term irreversible deterioration in the function of the kidneys often found in patients who also have diabetes and high blood pressure (HQIP)

Categories: Nephropathy, News
Tags: CKD

Categories: Nephropathy
Tags: CKD

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNovo NordiskSanofi DiabetesNapp Diabetes

Silver Sponsors

AmgenAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership